Management of chronic hepatitis C--time for a change?
Foster
Graham R
GR
Imperial College Faculty of Medicine at St Mary's, St Mary's Hospital, Praed Street, London W2 1PG, UK. g.foster@ic.ac.uk
D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D013997:Time Factors
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin